

AXIM BIOTECH TO ATTEND BIOCENTURY'S 24TH ANNUAL FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE IN NEW YORK

NEW YORK – April 5, 2017 – [AXIM[®] Biotechnologies, Inc.](#) (AXIM[®] Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at BioCentury's annual Future Leaders in the Biotech Industry Conference on April 7, 2017 at the Millennium Broadway Hotel & Conference Center in New York City.

Now in its 24th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

AXIM Biotech's presentation will be available on April 7th at this [link](#).

###

About AXIM[®]

AXIM[®] Biotechnologies, Inc. (OTC: [AXIM](#)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew[®], a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or

achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact

Andrew Hard

Chief Executive Officer

CMW Media

andrew.hard@cmwmedia.com

P. +1888 829-0070

www.cmwmedia.com

Investor Relations Contact

Shiwei Yin, Grayling

Shiwei.Yin@grayling.com

P. +1646 284-9474

Lucia Domville, Grayling

lucia.domville@grayling.com

P. +1646 284-9416

Corporate Contact Info

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227